A new tool for discovering drugs to treat neurological disorders
Official title: Ultra-High-Throughput Plate Reader for Drug Discovery Using All-Optical Electrophysiology
Funded at Quiver Bioscience INC. · NIH-11262016 · Data updated 2026-11-12
This study is working on a new tool that helps scientists quickly test new drugs for brain-related conditions by measuring how brain cells respond to different treatments, making it easier to find effective therapies for people.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Quiver Bioscience INC. NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project start | February 17, 2025 |
| Project end | August 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $51,450 |
| NIH project number | 3R44NS125689-07S1 |
| Project ID | NIH-11262016 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from neurological disorders who may benefit from new therapeutic options.
✕Less likely to help
Patients with non-neurological conditions or those not affected by neurological disorders may not receive any benefit from this research.
What this research studies
This research focuses on developing an ultra-high-throughput plate reader that uses all-optical electrophysiology to enhance drug discovery for neurological disorders. By utilizing advanced optogenetics tools, the instrument can simultaneously record voltage and calcium activity from multiple samples, allowing for rapid screening of potential therapeutic candidates. This innovative approach aims to overcome existing barriers in neuroscience drug discovery by providing scalable and translatable assays that can predict human efficacy more effectively.
Why it matters
Potential benefit: If successful, this research could lead to the development of new and more effective treatments for neurological disorders.
How similar studies have gone: Other research has shown promise in using advanced technologies for drug discovery, indicating that this approach could lead to significant advancements in the field.
Where this research is happening
-
Quiver Bioscience INC.
Cambridge, United States Active
Researchers
- Principal investigator: Lu, Yang — Quiver Bioscience INC.
- Study coordinator: Lu, Yang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.